Cellectis: Monthly Information on Share Capital and Company Voting Rights
March 06 2020 - 4:30PM
Business Wire
(Article 223-16 of General Regulation of the
French financial markets authority)
Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS):
Listing market: Euronext Growth
ISIN code: FR0010425595
Date
Total number of shares
in the capital
Total number of voting
rights
01/31/2020
42,465,669
51,239,422
About Cellectis Cellectis is developing the first of its
kind allogeneic approach for CAR-T immunotherapies in oncology,
pioneering the concept of off-the-shelf and ready-to-use
gene-edited CAR T-cells to treat cancer patients. As a
clinical-stage biopharmaceutical company with over 20 years of
expertise in gene editing, Cellectis is developing life-changing
product candidates utilizing TALEN®, its gene editing technology,
and PulseAgile, its pioneering electroporation system to harness
the power of the immune system in order to target and eradicate
cancer cells.
As part of its commitment to a cure, Cellectis remains dedicated
to its goal of providing life-saving UCART product candidates to
address unmet needs for multiple cancers including acute myeloid
leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and
multiple myeloma (MM).
Cellectis headquarters are in Paris, France, with additional
locations in New York, New York and Raleigh, North Carolina.
Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and
on Euronext Growth (ticker: ALCLS). For more information, visit
www.cellectis.com.
Follow Cellectis on social media: @cellectis, LinkedIn and
YouTube.
TALEN® is a registered trademark owned by Cellectis.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200306005375/en/
Media contacts: Jennifer Moore, VP, Communications,
917-580-1088, media@cellectis.com Caitlin Kasunich, KCSA Strategic
Communications, 212-896-1241, ckasunich@kcsa.com
IR contact: Simon Harnest, VP, Corporate Strategy and
Finance, 646-385-9008, simon.harnest@cellectis.com
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From May 2024 to Jun 2024
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Jun 2023 to Jun 2024